13F Holdings
中文EN

MANE Veradermics, Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1827635 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-11.7%
ROA-11.6%
ROIC (approx.)-13.2%
Asset turnover—

Leverage & solvency

Liabilities / assets1.3%
Debt / equity0.00x
Current ratio77.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$62.06M$23.28M
SG&A expense$10.28M$3.50M
Operating income-$72.35M-$26.78M
Interest expense$0$585,000
Pretax income-$70.00M-$26.49M
Income tax$0$0
Net income-$70.00M-$26.49M
EPS (basic)-111.91-37.05
EPS (diluted)-111.91-37.05
Weighted avg. shares (diluted)744,991736,933
Balance sheet
Cash & equivalents$21.77M$53.08M
Short-term investments$120.10M$0
Current assets$152.49M$55.53M
PP&E, net$22,000$0
Total assets$152.62M$55.53M
Current liabilities$9.15M$4.72M
Total liabilities$9.16M$4.72M
Shareholders' equity-$121.01M-$48.48M
Shares outstanding749,760736,933
Cash flow statement
Operating cash flow-$71.60M-$23.69M
Capital expenditure$24,000$0
Free cash flow-$71.63M-$23.69M
Investing cash flow-$118.86M$0
Financing cash flow$159.14M$60.48M
Stock-based compensation$1.44M$250,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.